phrykt

Traws Pharma, Inc. (TRAW): who owns it and who trades it

As of Nov 16, 2026, TRAW insiders reported 1 purchase worth $998K in the last 12 months. The largest buyer was OrbiMed Capital GP VIII LLC (10% owner), with $998K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Traws Pharma

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, TRAW insiders reported $998K of open-market purchases and $0 of sales.

Purchases, 12 months
$998K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Apr 16, 2026
Filed Apr 28, 2026

Purchases and sales by month

$998K$998KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 16, 2026OrbiMed Capital GP VIII LLC +110% ownerPurchase597,729$1.67$998KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
OrbiMed Capital GP VIII LLC10% owner$998K–Apr 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TRAW short interest

Low short interest. 4.4% of TRAW shares are sold short: about 1 share in 22. Over the last 12 reports the number of shares short went down 59%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 683,674 TRAW shares were sold short, 4.4% of the shares outstanding, down 0.3% from the report before. At the average daily volume of 165,069 shares, buying them all back would take about 4.1 trading days (days to cover).

Shares short, % of all shares

4.45%May 15Oct 3018.3%

Days to cover

4.1May 15Oct 309.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026683,6744.45%-0%165,0694.1
Oct 15, 2026685,7214.46%-1%184,5503.7
Sep 30, 2026690,6854.49%+13%2.78M1.0
Sep 15, 2026612,2163.98%-3%71,0758.6
Aug 31, 2026633,4234.12%+2%104,8066.0
Aug 14, 2026623,7604.06%-1%97,5526.4
Jul 31, 2026627,1686.17%-10%112,9155.5
Jul 15, 2026699,8506.89%-29%183,3083.8
Jun 30, 2026980,1449.65%-14%324,6083.0
Jun 15, 20261.13M11.17%-17%700,2891.6
May 29, 20261.38M13.54%-18%706,4891.9
May 15, 20261.67M16.45%+198%10.79M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Traws Pharma company events

Traws Pharma filed 18 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Oct 23, 2026.

  1. Oct 23, 2026AgreementTraws Pharma, Inc. entered into a Common Stock Purchase Agreement and a related Registration Rights Agreement, each dated as of October 23, 2026, with Roth Principal Investments, LLC. Filing
  2. Aug 14, 2026ResultsReleased financial results. Filing
  3. Jul 31, 2026ListingTraws Pharma, Inc. received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for at least 30 consecutive business days, the… Filing
  4. Jul 10, 2026AnnouncementAs previously disclosed in that Current Report on Form 8-K filed by Traws Pharma, Inc. with the Securities and Exhange Commission on March 10, 2025, on March 10, 2025, the Company entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC, pursuant to which the Company may… Filing
  5. Jul 9, 2026LeadershipAs described in Item 5.07 below, on July 8, 2026, at the 2026 Annual Meeting of Stockholders of Traws Pharma, Inc., the Company’s stockholders approved an amendment to the Company’s 2021 Incentive Compensation Plan (as so amended, the “Plan”), to increase the number of shares of common stock… Filing
  6. Jun 22, 2026AnnouncementShared information with investors. Filing
  7. Jun 12, 2026AnnouncementShared information with investors. Filing
  8. May 27, 2026AnnouncementShared information with investors. Filing
  9. May 26, 2026AnnouncementAs previously disclosed in that Current Report on Form 8-K filed by Traws Pharma, Inc. with the Securities and Exhange Commission on March 10, 2025, on March 10, 2025, the Company entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC, pursuant to which the Company may… Filing
  10. May 15, 2026ResultsReleased financial results. Filing
  11. Apr 15, 2026ResultsReleased financial results. Filing
  12. Apr 15, 2026AgreementTraws Pharma, Inc. announced the pricing of an offering of an aggregate of (i) 5,982,919 shares of the Company’s common stock, par value $0.01 per share (or, in lieu of Purchased Shares, pre-funded warrants to purchase shares of Common Stock), (ii) Series A warrants to initially purchase up to… Filing
  13. Feb 19, 2026AnnouncementTraws Pharma, Inc. issued a press release announcing the completion of its analysis of its study of ratutrelvir, a ritonavir-free treatment, in PAXLOVID®-eligible and ineligible patients with mild-to-moderate COVID-19 and updates for additional indication for tivoxavir marboxil as a prophylactic… Filing
  14. Jan 26, 2026AnnouncementTraws Pharma, Inc. issued a press release announcing the completion of its ongoing study of ratutrelvir, a ritonavir-free potential treatment, in PAXLOVID ® -eligible and ineligible patients with mild-to-moderate COVID-19, and plans for additional indication for tivoxavir marboxil as a prophylactic… Filing
  15. Jan 13, 2026AnnouncementTraws Pharma, Inc. issued a press release announcing the filing of a U.S. Investigational New Drug Application with the U.S. Food and Drug Administration for tivoxavir marboxil and providing updated results from its ongoing study of ratutrelvir, a ritonavir-free treatment, in PAXLOVID®-eligible and… Filing
  16. Dec 17, 2025AnnouncementTraws Pharma, Inc. issued a press release announcing positive interim data for its Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment, in newly diagnosed COVID subjects. Filing
  17. Dec 16, 2025LeadershipThe Compensation Committee of the Board of Directors of Traws Pharma, Inc. approved the grant of options to purchase shares of Company common stock and restricted stock units to the Company’s executive officers, as follows: 147,771 Options and 36,943 RSUs to Iain Dukes, the Company’s Chief… Filing
  18. Nov 28, 2025LeadershipAs described in Item 5.07 below, on November 21, 2025, at the 2025 Annual Meeting of Stockholders of Traws Pharma, Inc., the Company’s stockholders approved the amendment and restatement of the Company’s Amended and Restated 2021 Incentive Compensation Plan (as so amended and restated, the “Amended… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Traws Pharma financials

Famous investors that hold TRAW

1 of the 50 well-known investors we track reported holding TRAW in their latest 13F filing. The largest position is Ken Griffin's, worth $122K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026205,680$122K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TRAW in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Chernett Jorey13G/A0.0%
Nov 16, 2026Chernett Jorey13G/A0.0%

Questions about Traws Pharma, Inc. (TRAW) stock

Are TRAW insiders buying or selling?

In the last 12 months, TRAW insiders reported 1 open-market purchase worth $998K and no sales. The latest trade was on Apr 16, 2026. See every trade.

What is the short interest in TRAW?

As of Oct 30, 2026, 683,674 TRAW shares were sold short, 4.4% of the shares outstanding, down 0.3% from the report before. At the average daily volume of 165,069 shares, buying them all back would take about 4.1 trading days (days to cover). See the history.

Which famous investors hold TRAW?

1 of the 50 well-known investors we track reported TRAW in their latest 13F filing, including Ken Griffin. The largest position is worth $122K. See all holders.

Executive pay

Traws Pharma's chief executive was paid a total of $874K for the year ended Dec 31, 2025. In the last 12 months, Traws Pharma's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$874KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$670KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$874KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.